Brief: Galapagos Announces Start Of Papilio-1 Phase 1/2 Multiple Myeloma Study

Lakefront Biotherapeutics NV

19/12/2023 21:14

Dec 19 (Reuters) - Galapagos NV  GLPG.AS :
    * GALAPAGOS ANNOUNCES START OF PAPILIO-1 PHASE 1/2 MULTIPLE
MYELOMA STUDY OF POINT-OF-CARE MANUFACTURED BCMA CAR-T
CANDIDATE, GLPG5301
    * GALAPAGOS NV - DURING PHASE 1, UP TO 3 DOSE LEVELS WILL BE
EVALUATED AND AT LEAST 12 PATIENTS WILL BE ENROLLED TO ESTABLISH
RECOMMENDED PHASE 2 DOSE
    * GALAPAGOS NV - APPROXIMATELY 30 ADDITIONAL PATIENTS WILL
BE
ENROLLED IN PHASE 2 PART OF STUDY TO CONFIRM SAFETY AND EFFICACY
OF GLPG5301

Source text for Eikon:  ID:nGNX9Zp3PL 
Further company coverage:  GLPG.AS 

 ((Reuters.Briefs@thomsonreuters.com;))